ReviewJournal of personalized medicine2023
Active Surveillance for Prostate Cancer: Past, Current, and Future Trends.
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06661044 (Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploiting Human Microbiota-associated in Vivo Models for Mechanistic Studies to Understand the Benefits of Dietary Fibre Supplementation in Patients With Prostate Cancer
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Perceptions, Knowledge, and Attitudes of General Population About Prostate Cancer-Associated Risk Factors: A Systematic Review of Qualitative Studies Focusing on Lifestyle.Current oncology reports · 2025Pooled it
- Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study.Cancer medicine · 2026Article
- Lack of real-world evidence on active surveillance in Chinese patients with prostate cancer: insights from a 10-year cohort and a physician survey.BMC urology · 2026Observational
- Article
- Who, When, and How: Watchful Waiting in the ERSPC Rotterdam.European urology open science · 2026Article
- The predictive value of multiparametric magnetic resonance imaging in enhancing prostate-specific antigen assessment for prostate cancer: a cross-sectional study.Translational andrology and urology · 2026Article
- Exploring the optimal follow-up time for resectable colorectal cancer patients: a multicenter, five-year longitudinal cohort study.Scientific reports · 2026Article
- Is EQ-5D-5L sensitive enough to detect treatment-related changes in health status of prostate cancer patients? A nationwide Norwegian longitudinal study from the prostate cancer registry.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Review
- Global prostate cancer risk associated with microplastic exposure: a statistical and machine learning analysis.Frontiers in public health · 2026Article
- Standardizing Prostate MRI Reporting in Active Surveillance for Prostate Cancer: The PRECISE Framework.Journal of the Korean Society of Radiology · 2025Review
- Developing a digital psychosocial support program for men with low-risk prostate cancer during active surveillance.Internet interventions · 2025Article
- Article
- Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.BJU international · 2025Article
- Overdiagnosis and Overtreatment in Prostate Cancer.Diseases (Basel, Switzerland) · 2025Review
- The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.BJU international · 2025Article
- Tracking and analysis of benign prostatic hyperplasia and prostate cancer burden globally: 1990-2021 epidemiological trends.Translational andrology and urology · 2025Article
- Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance.Histopathology · 2025Article
- A Personalized, Risk-Based Approach to Active Surveillance for Prostate Cancer with Takeaways from Broader Oncology Practices: A Mixed Methods Review.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to the rising incidence of indolent, low-risk prostate cancer (PCa) due to increased prostate-specific antigen (PSA) screening in the 1990s, active surveillance (AS) emerged as a treatment modality to combat overtreatment by delaying or avoiding unnecessary definitive treatment and its associated morbidity. AS consists of regular monitoring of PSA levels, digital rectal exams, medical imaging, and prostate biopsies, so that definitive treatment is only offered when deemed necessary. This paper provides a narrative review of the evolution of AS since its inception and an overview of its current landscape and challenges. Although AS was initially only performed in a study setting, numerous studies have provided evidence for the safety and efficacy of AS which has led guidelines to recommend it as a treatment option for patients with low-risk PCa. For intermediate-risk disease, AS appears to be a viable option for those with favourable clinical characteristics. Over the years, the inclusion criteria, follow-up schedule and triggers for definitive treatment have evolved based on the results of various large AS cohorts. Given the burdensome nature of repeat biopsies, risk-based dynamic monitoring may further reduce overtreatment by avoiding repeat biopsies in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.